✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Alembic Pharmaceuticals Ltd.

APLLTD

Market Cap
₹18,836 Cr.
P/E
31.23

Alembic Pharmaceuticals Ltd.

  • Alembic Pharma
  • Astrazeneca Pharma I
  • Jubilant Pharmova
  • TJI Pharma
FAQs on Alembic Pharmaceuticals Ltd. Shareprice

Alembic Pharma has given lower returns compared to its competitors.
Alembic Pharma has grown at ~7.98% over the last 8yrs while peers have grown at a median rate of 14.58%

Yes, Alembic Pharma is expensive.
Latest PE of Alembic Pharma is 31.23, while 3 year average PE is 29.05.
Also latest EV/EBITDA of Alembic Pharma is 18.94 while 3yr average is 18.28.

View FAQ's On Business
Growth Table
  • Alembic Pharmaceuticals Ltd.
  • Astrazeneca Pharma I
  • Jubilant Pharmova
Balance Sheet
  • Alembic Pharmaceuticals Ltd.
  • Astrazeneca Pharma I
  • Jubilant Pharmova
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Alembic Pharmaceuticals Ltd.
  • Astrazeneca Pharma I
  • Jubilant Pharmova
Cash Flow
  • Alembic Pharmaceuticals Ltd.
  • Astrazeneca Pharma I
  • Jubilant Pharmova
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Alembic Pharmaceuticals Ltd.
  • Astrazeneca Pharma I
  • Jubilant Pharmova
Quarterly Results
  • Alembic Pharmaceuticals Ltd.
  • Astrazeneca Pharma I
  • Jubilant Pharmova
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Alembic Pharmaceuticals Ltd. Financials

Balance sheet of Alembic Pharma is strong.
But short term working capital might become an issue for this company.

Yes, The debt of Alembic Pharma is increasing.
Latest debt of Alembic Pharma is ₹1,016 Crs as of Mar-25.
This is greater than Mar-24 when it was ₹178 Crs.

The profit is oscillating.
The profit of Alembic Pharma is ₹601 Crs for TTM, ₹583 Crs for Mar 2025 and ₹616 Crs for Mar 2024.

The company seems to pay a good stable dividend.
Alembic Pharma latest dividend payout ratio is 37.06% and 3yr average dividend payout ratio is 39.38%

Companies resources are allocated to majorly unproductive assets like Inventory

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech